Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event. "Aspirin"

Recruiting

Phase N/A Results N/A

Trial Description

Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event.
The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences.
Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.

Conditions

Interventions

  • Aspirin Drug
    Other Names: clopidogrel; combination aspirin-dipyridamole
    Intervention Desc: Administration of 300 mg of aspirin, per os.
  • Blood sample Biological
    Intervention Desc: 2 blood samples will be performed

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Pharmacokinetics/Dynamics Study
  • Intervention: Single Group Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke 1 month No
Secondary Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated 1 month No

Sponsors